➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Medtronic
Baxter
Mallinckrodt
Colorcon

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Patent: 8,715,665

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,715,665
Title:Methods for treating cancer resistant to ErbB therapeutics
Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
Inventor(s): Janne; Pasi A. (Newton, MA), Engelman; Jeffrey (Chestnut Hill, MA), Cantley; Lewis C. (Cambridge, MA)
Assignee: The General Hospital Corporation (Boston, MA) Dana Farber Cancer Institute (Boston, MA) Beth Israel Deaconess Medical Center (Boston, MA)
Application Number:12/450,826
Patent Claims:see list of patent claims

Details for Patent 8,715,665

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial The General Hospital Corporation (Boston, MA) Dana Farber Cancer Institute (Boston, MA) Beth Israel Deaconess Medical Center (Boston, MA) 2027-04-13 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial The General Hospital Corporation (Boston, MA) Dana Farber Cancer Institute (Boston, MA) Beth Israel Deaconess Medical Center (Boston, MA) 2027-04-13 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial The General Hospital Corporation (Boston, MA) Dana Farber Cancer Institute (Boston, MA) Beth Israel Deaconess Medical Center (Boston, MA) 2027-04-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,715,665

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Harvard Business School
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.